infinity pharmaceuticals inc
(INFI:NASDAQ GS)

Executive Profile*

Background*

Dr. Julian Adams, Ph.D., has been the Chief Scientific Officer and Senior Vice President of Research & Development at Infinity Pharmaceuticals Inc. since October 2003. From December 1999 to October 2003, Dr. Adams served as a Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals. He joined Millennium Pharmaceuticals in December of 1999 following the Millennium's merger with LeukoSite Inc. where Dr. Adams served as a Senior Vice President ... of Research and Development. From 1994 to 1999, he served as an Executive Vice President of Research and Development at Proscript Inc. In 1987, Dr. Adams joined Boehringer Ingelheim where he served in various positions, including a Director of Medicinal Chemistry. From 1982 to 1987, Dr. Adams served as a Medicinal Chemist of Merck in Montreal. He has been a Director of Aileron Therapeutics Inc. since May 2011. He serves as a Director of Predix Pharmaceuticals Holdings Inc. and Predix Pharmaceuticals Inc. Dr. Adams serves as a Member of Scientific Advisory Board of Mediphase Venture Partners and BIND Biosciences, Inc. He served as a Member of Scientific Advisory Board at Verastem, Inc. He has been integrally involved in the discovery and development of two marketed drugs Velcade and Viramune. Dr. Adams is the Editor of a book on The Proteasome in Cancer. He holds a PhD from the Massachusetts Institute of Technology in the field of Synthetic Organic Chemistry and a BS from the McGill University.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
INFI:US	$23.12 USD	-2.01

COMPETITOR COMPENSATION